Phase 4 N=13 Randomized Triple-blind Treatment

Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction

Pulmonary Disease, Chronic Obstructive

Bottom Line

View on ClinicalTrials.gov: NCT02579772 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2018

Primary outcome: Primary: Plasma Redox Status - Circulating Glutathione — 8.97; 7.05 micromolar

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: N-acetylcysteine (Drug); Placebo (Drug)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: Queen's University
Primary completion: May 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Plasma Redox Status - Circulating Glutathione	8.97; 7.05	—
PRIMARY Exercise Capacity - Time to Exhaustion	336; 325	—
SECONDARY Change in Central Cardiovascular Function - Cardiac Output	12.5; 12.1	—
SECONDARY Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time)	19.0; 19.0	—
SECONDARY Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time)	65.4; 66.5	—
SECONDARY Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time)	63.0; 62.2	—
SECONDARY Change in Pulmonary Ventilation - Minute Ventilation (VE)	78.7; 75.8	—

Summary

The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow obstruction.

Eligibility Criteria

Inclusion Criteria

stable COPD with mild-to-moderate airflow obstruction as indicated by the low ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC 35kg/m²);
other diagnosed cardiorespiratory disorders (e.g., chronic heart failure, peripheral artery disease).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02579772). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.